Canopy Growth Secures EU-GMP Certification at Smiths Falls

Smiths Falls now covers softgels, oral liquids and flower

Canopy Growth's Smiths Falls facility is certified to EU-GMP standards for softgel manufacturing and for primary packaging of three product formats. Those formats are softgels, oral liquids and dried cannabis flower, according to Cannabis Business Times, which reported the news on Oct. 13, 2026.

The publication described the site as the only one in Canada that pairs softgel manufacturing with that packaging scope. Its summary said the certification "strengthens" Canopy Growth's European growth strategy and expands its integrated EU-GMP supply chain.

What the report leaves out

The signal doesn't name the certifying authority, the inspection date, or any capacity or revenue figure. Those gaps matter.

EU-GMP status typically follows an inspection by a national regulator, and the scope of the certificate defines what a site can legally ship. Until Canopy Growth or the issuing authority publishes the certificate details, the exact boundaries of the approval can't be verified. CannIntel hasn't seen the document itself.

On a strict reading, "only" does a lot of work

The "only" claim is narrow by construction: it applies to one combination of manufacturing and packaging capabilities at one site. On a strict reading, it doesn't say Canopy Growth is Canada's only EU-GMP operator, or even its only EU-GMP packager.

Other Canadian licensed producers hold EU-GMP status for various activities. The distinction is the pairing of softgel manufacturing with primary packaging across three formats. That's a real differentiator. A specific one.

Why EU-GMP status gates European sales

European medical cannabis buyers generally require GMP-compliant product, so certification determines which Canadian sites can ship at all. Germany, the region's largest medical market, is the most visible example of that demand.

Without the certificate, a Canadian site can grow and process excellent product and still be shut out. Certification is the ticket. Everything else is commercial.

The integration angle: fewer handoffs, fewer failure points

Combining manufacturing and primary packaging at one certified site cuts the number of GMP-audited transfers between a finished dose and the shipping pallet. Each handoff between facilities is a documentation, chain-of-custody and contamination risk.

For an operator, that's the practical case for the Smiths Falls scope. Fewer sites means fewer audits to pass and fewer places for a batch to be held up. That math is hard to argue with.

Oral liquids and dried flower add range beyond the softgel line. A buyer sourcing multiple formats could, in principle, qualify one supplier site rather than several.

The tax and compliance lens

IRC §280E, which bars deductions for U.S. businesses trafficking in Schedule I or II substances, doesn't reach a Canadian facility selling into Europe. The economics here run on different rules.

The costs that matter for a site like this are compliance costs: validation, quality systems, audits and recertification. How those are treated for tax purposes depends on Canadian and destination-country rules, and the signal says nothing about either. Investors should ask how much certification spending is capitalized versus expensed, and whether export margins justify it.

Not yet answerable. The filing trail will tell.

What to watch next

The certification is a capability, not a sales figure, and its value depends on European orders that follow. For full background on this story, see the CannIntel topic hub on Canopy Growth's EU-GMP expansion.

Three markers will show whether Smiths Falls pays off: published certificate scope from the issuing authority, European shipment volumes in Canopy Growth's next quarterly results, and any comment from the company on Health Canada export permits tied to the new formats. We'll be watching the earnings disclosure first.